Last reviewed · How we verify

FF/VI 100/25 Inhalation Powder NDPI — Competitive Intelligence Brief

FF/VI 100/25 Inhalation Powder NDPI (FF/VI 100/25 Inhalation Powder NDPI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination. Area: Respiratory/Pulmonology.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Beta-2 adrenergic receptor; glucocorticoid receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

FF/VI 100/25 Inhalation Powder NDPI (FF/VI 100/25 Inhalation Powder NDPI) — GlaxoSmithKline. FF/VI is a combination of fluticasone furoate (inhaled corticosteroid) and vilanterol (long-acting beta-2 agonist) that reduces airway inflammation and improves bronchodilation for chronic obstructive pulmonary disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
FF/VI 100/25 Inhalation Powder NDPI TARGET FF/VI 100/25 Inhalation Powder NDPI GlaxoSmithKline phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/fluticasone Diskus Salmeterol/fluticasone Diskus AstraZeneca marketed Long-acting beta-2 agonist/inhaled corticosteroid combination Beta-2 adrenergic receptor; glucocorticoid receptor
Extra fine Formoterol/Beclomethasone Extra fine Formoterol/Beclomethasone National Institute of Respiratory Diseases, Mexico marketed Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/Fluticasone Capsair® Salmeterol/Fluticasone Capsair® Neutec Ar-Ge San ve Tic A.Ş marketed Long-acting beta-2 agonist/inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; glucocorticoid receptor
Seretide 500 Accuhaler Seretide 500 Accuhaler University of Southampton marketed Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/ fluticasone propionate Salmeterol/ fluticasone propionate GlaxoSmithKline marketed Long-acting beta-2 agonist / inhaled corticosteroid combination Beta-2 adrenergic receptor; glucocorticoid receptor
Seretide Accuhaler® 500/50 µg/actuation Seretide Accuhaler® 500/50 µg/actuation Chiesi Farmaceutici S.p.A. phase 3 Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) Beta-2 adrenergic receptor; glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination class)

  1. GlaxoSmithKline · 14 drugs in this class
  2. Pearl Therapeutics, Inc. · 5 drugs in this class
  3. AstraZeneca · 4 drugs in this class
  4. Research in Real-Life Ltd · 3 drugs in this class
  5. Chiesi Farmaceutici S.p.A. · 2 drugs in this class
  6. Istituto per la Ricerca e l'Innovazione Biomedica · 1 drug in this class
  7. Johns Hopkins University · 1 drug in this class
  8. National Jewish Health · 1 drug in this class
  9. SkyePharma AG · 1 drug in this class
  10. University Medical Center Groningen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FF/VI 100/25 Inhalation Powder NDPI — Competitive Intelligence Brief. https://druglandscape.com/ci/ff-vi-100-25-inhalation-powder-ndpi. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: